文献速递中医内科中药与中成药合理使用

丹参川芎嗪注射液治疗急性脑梗死的安全性与有效性:一项符合PRISMA的荟萃分析

Safety and effectiveness of Salvia miltiorrhiza and ligustrazine injection for acute cerebral infarction in Chinese population: a PRISMA-compliant meta-analysis.
PubMed 文献 · Front Pharmacol · 2024-12-02

该荟萃分析纳入38项随机对照试验、共3869例急性脑梗死患者,评估丹参川芎嗪注射液(SML)联合常规治疗的疗效与安全性。结果显示联合治疗可显著提高总有效率、改善神经功能与日常生活能力,且不良事件发生率与常规治疗组无显著差异。结论认为联合治疗更安全有效,但受地域偏倚与发表偏倚限制,需前瞻性高质量多中心试验进一步验证。

要点

  • SML联合常规治疗可显著提高急性脑梗死患者总有效率(RR=1.23)。
  • 联合治疗可改善神经功能(NIHSS评分降低)与日常生活能力(Barthel指数提高)。
  • 两组不良事件发生率无显著差异(RR=1.49,95%CI 0.91-2.46,P=0.11)。

核心结论

  • 荟萃分析证据提示,常规治疗联合丹参川芎嗪注射液治疗急性脑梗死比单用常规治疗更安全有效。
  • 受地域偏倚与发表偏倚等局限影响,上述结论需前瞻性高质量多中心临床试验进一步验证。

研究设计与样本

  • 系统检索Cochrane Library、Web of Science、Embase、Medline、PubMed、CSJD、万方、CBM和CNKI等数据库(建库至2023年5月)的随机对照试验。
  • 最终纳入38项试验、共3869例急性脑梗死患者,按PRISMA声明进行系统综述与荟萃分析。

主要发现

  • 联合治疗组总有效率显著高于常规治疗组(RR=1.23,95%CI 1.20-1.27,P<0.00001)。
  • 联合治疗组NIHSS评分改善显著优于常规治疗组(MD=-4.35,95%CI -5.15至-3.54,P<0.00001)。
  • 联合治疗组Barthel指数评分改善显著优于常规治疗组(MD=10.27,95%CI 7.75-12.79,P<0.00001)。
  • 联合治疗后血液流变学指标显著改善(P<0.05)。
  • 两组不良事件发生率无显著差异(RR=1.49,95%CI 0.91-2.46,P=0.11)。

关键数值与推荐

  • 总有效率:RR=1.23,95%CI 1.20-1.27,P<0.00001。
  • NIHSS评分:MD=-4.35,95%CI -5.15至-3.54,P<0.00001。
  • Barthel指数评分:MD=10.27,95%CI 7.75-12.79,P<0.00001。
  • 不良事件:RR=1.49,95%CI 0.91-2.46,P=0.11。

临床怎么用

  • 对急性脑梗死患者,可考虑在常规治疗基础上联合丹参川芎嗪注射液以改善总有效率、神经功能与日常生活能力。
  • 联合用药时不良事件发生率与常规治疗相当,但仍需关注个体化用药与监测。

局限性

  • 分析存在地域偏倚与发表偏倚等局限。
  • 结论需前瞻性、高质量、多中心临床试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salvia miltiorrhiza and ligustrazine injection (SML) is a type of traditional Chinese medicine injection, which has been considered a promising adjunctive therapy treatment for acute cerebral infarction (ACI). Although there have been positive reports on the treatment of SML, there is still controversy over its exact efficacy and safety in ACI patients. In this study, a systematic review was conducted on randomized controlled trials (RCTs) of SML for the treatment of ACI to evaluate its clinical efficacy and safety. METHOD: From the establishment of the database until May 2023, all randomized controlled trials related to SML and ACI were collected from the Cochrane Library, Web of Science, Embase, Medline, PubMed, CSJD, Wanfang database, CBM and CNKI. This systematic review and meta-analysis were strictly conducted in accordance with the PRISMA statement. The reported outcomes including overall response (ORR), National Institutes of Health Stroke Scale (NIHSS), hemorrheology indexes, activity of daily living (ADL) and adverse events were in detail investigated. RESULTS: An analysis was conducted on the relevant data of 3869 ACI patients from 38 trials. The results indicated that the combination of conventional treatment and SML can significantly improve the ORR of patients (RR = 1.23, 95% CI = 1.20-1.27, P < 0.00001), neurological status (NIHSS, MD = -4.35, 95% CI = -5.15-3.54, P < 0.00001) and ADL (Barthel Index score, MD = 10.27, 95% CI = 7.75-12.79, P < 0.00001) compared with regular treatment alone. After the combined therapy, the hemorheology of ACI patients also significantly improved (P < 0.05). There is no significant difference in the frequency of adverse events between the two groups (RR = 1.49, 95% CI = 0.91-2.46, P = 0.11). CONCLUSION: The evidence from the meta-analysis suggested that the combination of conventional therapy and SML is safer and more effective than conventional therapy alone in treating ACI. However, due to the limitations of this analysis, such as regional bias and publication bias, the above conclusions need to be further verified by prospective, high-quality and multicenter clinical trials.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ma Z, Zhang H, Zhao F, et al. Safety and effectiveness of Salvia miltiorrhiza and ligustrazine injection for acute cerebral infarction in Chinese population: a PRISMA-compliant meta-analysis. Front Pharmacol. 2024. PMID: 39687295. doi:10.3389/fphar.2024.1425053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。